Provista Diagnostics has entered into an agreement with Lpath to create new laboratory tests targeting significant gaps in early ovarian cancer detection. The Scottsdale, Ariz.-based Provista, which focuses on molecular-based cancer diagnostic testing, said the parties would focus their collaboration on a bioactive known as lipid lysophosphatidic acid, or LPA, which can be an indicator…
Industry Buzz: Provista Teams With Lpath to Improve Ovarian Cancer Tests
Provista Diagnostics has entered into an agreement with Lpath to create new laboratory tests targeting significant gaps in early ovarian cancer detection. The Scottsdale, Ariz.-based Provista, which focuses on molecular-based cancer diagnostic testing, said the parties would focus their collaboration on a bioactive known as lipid lysophosphatidic acid, or LPA, which can be an indicator […]